Attivare Therapeutics, a biotechnology company founded by a dedicated team from Harvard University's Wyss Institute, is set to showcase the clinical pre-data of its two novel anticancer drugs, ATT-01 and ATT-02, at the 2025 American Association for Cancer Research (AACR) annual meeting. These drugs are part of the company's ATTimmune platform, which uses biodegradable silica-based scaffolds to create new physical microenvironments within the body, attracting and activating immune cells to tackle both solid tumors and blood cancers. ATT-01: Silica-Based Scaffold for AML Treatment ATT-01 is a degradable silica scaffold (Mesoporous Silica Rods, MSR) loaded with GM-CSF and CpG. Clinical pre-data indicates that this combination can induce differentiation of acute myeloid leukemia (AML) cells in vitro and significantly enhance vaccine-like T cell responses. In a syngeneic AML tumor model, ATT-01 achieved sustained remission, offering promising evidence for a new approach to immunotherapy for AML. This breakthrough demonstrates how ATT-01 can effectively stimulate the patient's immune system to target and eliminate AML cells. ATT-02: Enhanced Antitumor Immunity with IL-12 ATT-02 builds on the ATTimmune platform by incorporating Interleukin-12 (IL-12) for intratumoral injection. Compared to IL-12 alone, ATT-02 shows a more potent antitumor immune response. A single dose of ATT-02 resulted in complete remission in two colon cancer models (one local and one distant effect). Even without IL-12, the ATTimmune scaffold itself demonstrated some efficacy in slowing tumor growth and promoting the transformation of macrophages to an immune-activating phenotype in vitro. The addition of IL-12 further amplified these effects. The ATTimmune Platform: A Game-Changer in Drug Delivery The ATTimmune platform is designed to deliver high concentrations of potent immunostimulants directly to the tumor site. It can carry various therapeutic agents, including biologics, small molecules, gene therapies, and even cell technologies, without altering their properties. The scaffold's large size ensures it remains in place after injection, maintaining drug concentration in the tumor microenvironment for up to 21 days. This sustained release reduces or eliminates systemic toxicity, a significant advantage over conventional treatment methods. David Sherris, President and CEO of Attivare Therapeutics, expressed excitement about the upcoming presentation: "We are thrilled to present the clinical pre-data of ATT-01 and ATT-02 at the AACR annual meeting. The ATTimmune platform is a revolutionary silica-based technology that effectively delivers powerful immune activators to fight cancer. Our ability to combine multiple treatments without compromising their characteristics and to maintain high drug concentration locally for extended periods sets us apart.” Company Profile: Attivare Therapeutics Attivare Therapeutics is a pioneering biotech company focused on overcoming the challenges of treating low immunogenic tumors. Their ATTimmune platform leverages proprietary biodegradable materials to recruit, reprogram, and release targeted immune cells, providing unprecedented three-dimensional spatiotemporal control over immune responses. This technology not only enhances the strength and duration of patients' immune reactions but also integrates seamlessly with standard treatments. Additionally, it holds promise for applications beyond cancer, such as treating infectious diseases. Industry Insights and Evaluations Industry experts have praised Attivare Therapeutics for its groundbreaking work in precise drug delivery and reducing side effects. The unique design of the ATTimmune platform is seen as a significant step forward in immunotherapy. By enhancing immune cell function and improving treatment outcomes, Attivare's technology offers new pathways for tackling cancer and potentially other diseases. With multiple patents filed globally, Attivare Therapeutics is committed to translating its innovative research into practical therapies. The presentation of ATT-01 and ATT-02 at the AACR annual meeting will likely attract substantial interest and further validate the potential of bioengineered scaffolds in cancer immunotherapy. The company's focus on creating microenvironments that support a robust and sustained immune response aligns closely with the growing trend in personalized medicine, where treatments are tailored to individual patients' needs. As Attivare continues to develop its technology, it is poised to make a significant impact on the future of oncology and beyond.